You can find details about how to access information remotely in this step-by-step guide. The guide will also help if for any reason you have difficulty accessing the content you want.
Molecular Omics publishes high-quality research in the -omics sciences. We welcome scientific research based on the application of any -omics technology and we encourage multi-omics approaches to solving important chemical or biological problems. This includes combining different types of omics platforms encompassing genomics, transcriptomics, proteomics, metabolomics and other specialized areas such as glycomics and lipidomics, as well as innovative bioinformatics approaches.
What would you like to know about this journal?
Molecular Omics is a Transformative Journal, and Plan S compliant
Impact factor: 4.212*
Time to first decision (all decisions): 11.0 days**
Time to first decision (peer reviewed only): 49.0 days***
Chair: Robert Moritz
Indexed in Web of Science, Scopus and MEDLINE
A trusted editorial team
Our rigorous peer review process ensures transparency, fairness and balance
Open Access options
We can help you improve the visibility of your work and meet funder mandates
No cost to publish
We don't charge submission, page or colour charges - and we offer free electronic reprints
We accept submissions of manuscripts that have previously been posted as pre-prints
Copyright is yours
We believe the copyright of your work should always belong to you, so we only ask for a licence to publish it
A focus on community
Because the Royal Society of Chemistry re-invests all surplus back into the global scientific community, you can raise your profile and support international scientific progress at the same time
Molecular Omics publishes high-quality research from across the -omics sciences.
Topics include, but are not limited to:
- omics studies to gain mechanistic insight into biological processes – for example, determining the mode of action of a drug or the basis of a particular phenotype, such as drought tolerance
- omics studies for clinical applications with experimental validation, such as finding biomarkers for diagnostics or potential new drug targets
- omics studies looking at the sub-cellular make-up of cells – for example, the subcellular localisation of certain proteins or post-translational modifications or new imaging techniques
- studies presenting new methods and tools to support omics studies, including new spectroscopic/chromatographic techniques, chip-based/array technologies and new classification/data analysis techniques. New methods should be proven and demonstrate an advance in the field.
Molecular Omics only accepts articles of high importance and interest that provide significant new insight into important chemical or biological problems. This could be fundamental research that significantly increases understanding or research that demonstrates clear functional benefits.
Papers reporting new results that could be routinely predicted, do not show a significant improvement over known research, or are of interest only to the specialist in the area are not suitable for publication in Molecular Omics.
Meet the team
Find out who is on the editorial and advisory boards for the Molecular Omics journal.
Robert Moritz, Institute for Systems Biology, Seattle USA
Hyungwon Choi, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Richard Unwin, University of Manchester, UK
Editorial board members
Celia Berkers, Utrecht University, Netherlands
Subhra Chakraborty, National Institute of Plant Genome research (NIPGR), New Delhi, India
Benjamin Garcia, Washington University in St Louis, Missouri, USA
Nicolle Packer, Macquarie University, Sydney, Australia
Xiaohua Shen, Tsinghua University, China
Michael Washburn, University of Kansas Medical Center, USA
Chris Bakal, Institute of Cancer Research, UK
Anne K Bendt, National University of Singapore, Singapore
Tunahan Cakir, Gebze Technical University, Turkey
Erin Carlson, University of Minnesota, USA
James Edwards, Saint Louis University, USA
Claire Eyers, University of Liverpool, UK
Alex Georgakilas, East Carolina University, USA
Rebekah Gundry, University of Nebraska Medical Center, USA
Walter Kolch, System Biology Ireland, Dublin, Ireland
Ben Lehner, Center for Genomic Regulation, Spain
Souvik Maiti, Institute of Genomics and Integrative Biology,India
Andrej Shevchenko, Max Planck Institute for Molecular Cell Biology and Genetics, Germany
Silke Sperling, Max Planck Institute for Molecular Genetics, Berlin, Germany
Ed Tate, Imperial College London, UK
Ronghu Wu, Georgia Institute of Technology, USA
Rebecca Garton, Executive Editor
Jack Washington, Deputy Editor
Daniel Robertshaw, Development Editor
Sarah Whitehouse, Editorial Production Manager
Nicola Burton, Publishing Editor
Tom Cozens, Publishing Editor
Katie Fernandez, Publishing Editor
Ryan Kean, Publishing Editor
Roxane Owen, Publishing Editor
Alex Rowles, Publishing Editor
Andrea Whiteside, Publishing Assistant
Molecular Omics publishes:
- Research articles
Submitting a Review
If you are interested in submitting a review, please complete a Review proposal form and email the Editorial Office.
All new research in Molecular Omics is published in the Research Article format. Research Articles have no page limits, although most articles fall between 4 and 10 journal pages (approximately 10–25 pages of double-spaced text).
Research findings should be presented in an informative way, emphasising the importance and potential impact of the research. Authors should limit experimental procedures and data in the main text to a maximum two journal pages (approximately 5 double-spaced pages), with all additional experimental information and data placed in the electronic supplementary information (ESI).
Authors are particularly encouraged to prepare a title and abstract which concisely summarise the key findings of their research and their importance, avoiding the use of non-standard abbreviations, acronyms and symbols, as this will enable potential readers to quickly understand the significance of the research. Authors should also consider using recognisable, searchable terms, as around 70% of our readers come directly via search engines. The table of contents graphic should give the reader a clear indication of the topic of the study, for example by showing key compounds.
Authors are encouraged to use the article template, available from our Author templates & services page, for preparing their submissions. However, the use of the template for Research Article submissions is not essential.
Additional guidance on the layout and formatting of the article and supplementary information can be found on our Prepare your article page.
Molecular Omics reviews are a concise and critical appraisal of an important area in omics science or a related topic, typically 6–12 journal pages in length (approximately 15-30 pages of double-spaced text).
Reviews should focus on the key developments that have shaped the topic, rather than comprehensive reviews of the literature. Authors are encouraged to include their own perspective on developments, trends and future directions, particularly identifying areas where further developments are imminent or that are in urgent need of being addressed. Please note that Reviews should include balanced coverage of the field and not focus predominantly on the author’s own research. Reviews should not include new research results.
We welcome suggestions from authors for Reviews. If you are interested in writing a Review for the journal, please contact the editorial office.
Comments and Replies are a medium for the discussion and exchange of scientific opinions between authors and readers concerning material published in Molecular Omics.
For publication, a Comment should present an alternative analysis of and/or new insight into the previously published material. Any Reply should further the discussion presented in the original article and the Comment. Comments and Replies that contain any form of personal attack are not suitable for publication.
Comments that are acceptable for publication will be forwarded to the authors of the work being discussed, and these authors will be given the opportunity to submit a Reply. The Comment and Reply will both be subject to rigorous peer review in consultation with the journal’s Editorial Board where appropriate. The Comment and Reply will be published together.
Journal specific guidelines
Data requirements for submission
The Royal Society of Chemistry believes that, where possible, all data associated with the research in a manuscript should be Findable, Accessible, Interoperable and Reusable (FAIR), enabling other researchers to replicate and build on that research. Molecular Omics strongly encourages authors to deposit as much data as possible in appropriate repositories.
All data required to understand and verify the research in an article must be made available on submission, and should be made available in the following ways:
- All original raw datasets essential for the results and conclusion of the manuscript, especially X-Ray crystallographic data and macromolecular structure and sequence data, should be deposited in publicly available repositories (find list of recommended databases in the respective sections below), and accession numbers should be provided in the manuscript. As an alternative the datasets should be presented in the ESI in a machine-readable format (for example, spreadsheets instead of pdf).
- All other required data, for example, small molecule characterisation data, should be submitted as electronic supplementary information. See also our general RSC guidelines for experimental data for additional information.
Referees should be able to access those data during the peer-review process, and public release should be coordinated with publication of the manuscript.
In order to maintain high standards of transparency, research reproducibility, and to promote the reuse of new findings, Molecular Omics requests authors to include a Data Availability Statement as part of the final published article. Exceptions to this would be at the Editor’s discretion. Further information on Data Availability Statements can be found below.Data submission information
For experiments involving microorganisms sufficient detail should be provided to identify the species being used. Specific info on antibodies is essential. Commercial sources and if new antibodies are generated full experimental details such as immunogen/phage, species, protocols for mAb) should be given. We strongly recommend authors to use unique Resource Identifiers for model organisms, antibodies and tools and publish them with full descriptions.
For biomarker discovery and validation studies scatter plots of data, sensitivity and specificity values with confidence intervals and results of receiver operating characteristic curve analysis should be at least presented. If a marker is already routinely used for that disease, comparison with that marker should be included.
For genetically modified organisms and mutants appropriate repositories such as the UK Stem Cell Bank, the Maerican Type Culture Centre and the Jackson Laboratory should be used. Larger datasets might be given in the ESI instead.
a) Biological materials
|Cell lines, tissue biopsies, environmental isolates, Plasmids, DNA||BioSample database, Addgene or PlasmID|
b) Phylogenetic data
Statistical methods should be presented with full information and their appropriateness for the test should be stated in manuscript.
Models of biochemical reaction networks are represented by a computer-readable format: the Systems Biology Markup Language (SBML). SBML is applicable to metabolic networks, cell-signalling pathways, regulatory networks, and many others. We encourage authors to prepare models of biochemical reaction networks using SBML and to deposit the model with the BioModels database. Authors may submit datasets in SBML formats, when they are available, for publication as electronic supplementary information.
All mathematical models should be submitted alongside all necessary parameters to program the model (reaction conditions and stoichiometrics, rate equations, etc).
Authors should make new software applications as well as custom codes available for testing by reviewers preserving their anonymity. A link should be provided to access to newest version online and the archived version should be referenced in the manuscript. Both should be archived in a suitable repository and unique identifiers should be given in the manuscript. The software should be directly available for non-commercial usage without restrictions.
Atomic coordinates fitted to EM maps should be deposited to an appropriate database (and released upon publication) and accession numbers should be included in the manuscript. Deposition of relevant information in appropriate databases is highly recommended (for example, the Worldwide Protein Data Bank, Protein Data Bank Japan, Protein Data Bank in Europe, the Electron Microscopy Data Bank or the EMDataBank).
a) Functional genomics data/deep sequencing data (such as microarray, RNA-seq or ChIP-seq data)
Functional genomics data (for example, microarray, RNA-seq or ChIP-seq data) should follow the standards proposed by the Functional Genomics Data Society.
Gene nomenclature should be standardised with human gene names and symbols from a gene nomenclature database.
For unpublished genomic data the guidelines of the Fort Lauderdale and Toronto agreements should be followed and the authors should contact the owner of the genomic data before starting their research.
Genomic data generated from HeLa cells: We highly recommend authors to comply with the NIH HeLa Genome Data Use Agreement.
|Expression, epigenetics, phenol- or genotypes, genomic variants (GWAS studies), human sequence data||Database of Genotypes and Phenotypes (dbGaP)|
|Protein-protein, protein-DNA/RNA and molecular interactions||The IntAct molecular interaction database (IntAct)|
|miRNA sequences and annotation||miRBase|
|Human genomic data, genetic polymorphisms||dbSNP, the Database of Genomic Variants Archive (DGVa), Database of Genomic Structural Variation (dbVAR)|
b) Sequence variants
Nucleic acids sequences and variation
|Nucleic acid sequences||DNA Data Bank of Japan (DDBJ), European Molecular Biology Laboratory (EMBL/EBI) Nucleotide Sequence Database, GenBank (National Center for Biotechnology Information), NCBI Sequence Read Archive (SRA), ENA’s Sequence Read Archive, NCBI Trace Archive|
|Variations||dbSNP, European Variation Archive (EVA), dbVar, Database of Genomic Variants Archive (DGVa)|
|Metagenome, sequence alignment, sequence information||EBI Metagenomics|
|Protein sequences||Universal Protein Resource (UniProt)e|
Mass spectrometry data should be provided in the mzML format following the HUPO Protein Standards Initiative guidelines; for peptide mass fingerprinting the total percentage of sequence coverage and number of peptides matching it should be given.
Mass spectrometric analysis and quantification of proteins and peptides: the authors should provide detailed information on how raw data was converted into a format for database searching (for example, peak list from raw MS or MS/MS data), the search engine used, the database(s), scoring function(s), false discovery rate (how calculated) and statistical methods employed.
For post-translational protein modifications results of fragmentation analysis and spectra should be provided. If no evidence for assigning a modification to a single amino acid is provided it should be reported as ambiguous.
To ensure reproducibility, please provide experimental details for (gel-based) proteomics data such as how the duplicates were performed and how the data was processed with what standard.
|Protein interaction||MEx consortium|
Metabolomics data should follow the standards of the Metabolomics Society. If your work is part of the NIH Common Fund Metabolomics Program supported research projects, your data should also be compliant with their guidelines.
|Metabolomics||MetaboLights, Metabolomics Data Repository|
Microarray data should be MIAME compliant and deposited in an appropriate database (for example, GEO or ArrayExpress). Accession numbers should be given in the manuscript.
a) Macromolecular structures
|Protein structures||Worldwide Protein Data Bank, Biological Magnetic Resonance Data Bank (BMRB)|
|Nucleic acid structures||Nucleic Acid Database|
|Imaging (all types)||Coherent X-ray Imaging Data Bank (CXIDB)|
For macromolecular NMR and crystal data please refer to the general RSC experimental data guidelines.
b) Chemical structures & assays
Structural data for small molecules should be presented in the manuscript ESI. However we would encourage authors to publicly deposit as much data as possible that is related to the research in their article.
|Chemical structures||PubChem Substance|
|Bioactivity assays||PubChem BioAssay|
|Nanomaterials and their composition and physico-chemical and in vitro characterisations||caNanoLab|
|Flow cytometry data||Flow Repository|
For single molecule crystal data and NMR data please refer to the general RSC experimental data guidelines.
Data availability statements
Data availability statements (DAS) provide information about where data, software or code supporting the results reported in a published article can be found. These should include, where applicable, links to datasets shared in an external data repository, which have been analysed or generated during the study. This section should list the database, accession number, DOI, URL or any other relevant details. Authors are also encouraged to formally cite associated datasets in the reference section of an article.
The DAS can provide information about the data presented in an article (e.g. in Figures or Tables) or provide a reason if data is not available to access. If supporting data or code have been included in the article’s electronic supplementary information (ESI), this should also be stated here.
A Data Availability Statement should be included at the end of the article, after the Conclusions section. Examples of Data Availability Statements which can be used are shown below:
- The datasets supporting this article have been uploaded as part of the supplementary material.
- The code for [description of ] can be found at [URL] with [DOI – if available].
- Data for this paper, including [description of data types] are available at [name of repository] at [URL – format https://doi.org/DOI].
- This study was carried out using publicly available data from [name of repository] at [URL] with [accession number].
The following statement is generally not acceptable “Data are available upon request from the authors".
Post-acquisition processing of data
All image acquisition and processing tools (including their settings) should be clearly stated in the manuscript. The amount of post-acquisition processing of data should be kept to a minimum. Any type of alteration such as image processing, cropping and groupings should be clearly stated in the figure caption and the ESI (clearly describing the process of alteration). Data manipulation (for example, normalisation or handling of missing values) should be given.
Image processing changes should be applied to the entire image as well as all other images it is compared to. Processed images should still represent all the original data (with no data missing) and touch-up tools should be avoided.
All Western blot and other electrophoresis data should be supported by the underlying raw images. The image of the full gel and blot, uncropped and unprocessed, should be provided in the supplementary information on submission. All samples and controls used for a comparative analysis should be run on the same gel or blot. For each blot and gel, all positive and negative controls and molecular size markers (for example, protein ladder) should be shown (if not in the main figure at least in the ESI). Only results of comparable experiments should be compared.
When illustrating the blot or gel result, any cropping or rearrangement of lanes within an image should be stated in the figure legend and with lane boundaries clearly delineated. Important bands should not be cropped in gels and cropped blots should retain at least six band widths above and below the band. Alterations should be kept to a minimum required for clarity.
Each blot or gel image should be appropriately labelled, with closest molecular mass markers and lanes labelled. All details must be visible, over or underexposed gels and blots are not acceptable; a grey background is highly encouraged. Authors should be able to provide raw data for all replicate experiments upon request.
Genuine and relevant signals in spectra must not be lost due to image enhancement.
Microscopy images of cells from multiple fields should not be compared but shown as single images (at least in the ESI).
Authors might be asked during peer review to provide the original unprocessed data to the editors/reviewers of the journal.
Guidelines on writing titles, abstracts & table of contents entry
The title, abstract and table of contents entry (graphical abstract) are the first parts of your manuscript that editors, referees and potential readers will see, and once published they play a major part in a researcher’s decision to read your article. Therefore it’s important that these clearly and concisely show the main findings of your research and why they are important.More information on writing titles, abstracts & table of contents
The title should be short and straightforward to appeal to a general reader, but detailed enough to properly reflect the contents of your review article.
- Keep it relatively short – between 8 and 15 words is ideal.
- Use easily recognisable words and phrases that can be read quickly.
- Use general or well-known terms for compounds and procedures rather than very specialised terms or nomenclature.
- Avoid using non-standard abbreviations and symbols.
- Avoid using subjective terms such as “novel”.
- Use keywords and familiar, searchable terms – these can increase the chances of your article appearing in search results. Around 70% of our readers come directly via search engines.
The abstract is a single paragraph which summarises the contents of your article. It will help readers to decide whether your article is of interest to them.
- The length can vary from 50 to 250 words (or 40 to 75 words for Communications), but it should always be concise and easy to read with recognisable words and phrases.
- It should set out the objectives of the work, the key findings and why this research is important (compared to other research in its field).
- It should emphasise (but not overstate) the significance and potential impact of the research in your article.
- Avoid including detailed information on how the research was carried out. This should be described in the main part of the manuscript.
- Like your title, make sure you use familiar, searchable terms and keywords.
Table of contents entry
A table of contents entry (graphical abstract) is required, which should be submitted at the revision stage. This should include an eye-catching graphic and 1-2 sentence(s) of text to summarise the key findings of the article to the reader. It will appear in the table of contents and feeds – for example, RSS feeds.
The graphic should:
- Be simple, but informative.
- Capture the reader’s attention (the use of colour is encouraged).
- Include a structure, scheme, graph, drawing, photograph or combination that conveys the message of the article. Please note, complex schematics or spectra should be avoided.
- Be original, unpublished artwork created by one of the co-authors. Preferably, the graphic should not be reused and appear again within the article.
- Be suitable for, and uphold the standards of, a scholarly publication that has a global reach.
- Not contain any elements that are offensive or inappropriate, in particular words or images that are discriminatory.
- Not contain graphic images of animal or human testing or surgery.
- Not contain large amounts of text. Text should be limited to the labelling of compounds, reaction arrows and diagrams, with long phrases or sentences being avoided. Any text should be clearly legible to a reader.
- Not contain logos, trademarks or brands names.
The text should:
- Be concise and focus only on the key findings of the manuscript and their importance, not the processes used; think about what would grab the attention of the potential reader and would encourage them to read the full article.
- Avoid repeating or paraphrasing the title or abstract.
- Use easily recognisable words and phrases that can be read quickly.
Table of contents specifications:
- The figure should be a maximum size of 8 cm wide x 4 cm high.
- Figures should be supplied as TIFF files, with a resolution of 600 dpi or greater.
- The text supplied should be 1-2 sentences long, using a maximum of 250 characters.
Open access publishing options
Molecular Omics is a hybrid (transformative) journal and gives authors the choice of publishing their research either via the traditional subscription-based model or instead by choosing our gold open access option. Find out more about our Transformative Journals. which are Plan S compliant.
Gold open access
For authors who want to publish their article gold open access, Molecular Omics charges an article processing charge (APC) of £2,500 (+ any applicable tax). Our APC is all-inclusive and makes your article freely available online immediately, permanently, and includes your choice of Creative Commons licence (CC BY or CC BY-NC) at no extra cost. It is not a submission charge, so you only pay if your article is accepted for publication.
Learn more about publishing open access.
Read & Publish
If your institution has a Read & Publish agreement in place with the Royal Society of Chemistry, APCs for gold open access publishing in Molecular Omics may already be covered.
Check if your institution is already part of our Read & Publish community.
Please use your official institutional email address to submit your manuscript; this helps us to identify if you are eligible for Read & Publish or other APC discounts.
Traditional subscription model
Authors can also publish in Molecular Omics via the traditional subscription model without needing to pay an APC. Articles published via this route are available to institutions and individuals who subscribe to the journal. Our standard licence allows you to make the accepted manuscript of your article freely available after a 12-month embargo period. This is known as the green route to open access.
Researchers from industry and academia interested in molecular level research in proteomics, transcriptomics and metabolomics, genomics and other omics science.
Thus the journal will appeal to a wide variety of researchers, but particularly to the folllowing.
- Chemical biologists
- Biological chemists
- Molecular and structural biologists
- Drug discovery scientists
- Protein chemists
- Bio- and cheminformaticians
- Organic and analytical chemists
Online only 2023: £1,430 / $2,520
*2021 Journal Citation Reports (Clarivate Analytics, 2022)
**The median time from submission to first decision including manuscripts rejected without peer review from the previous calendar year
***The median time from submission to first decision for peer-reviewed manuscripts rejected from the previous calendar year
****CiteScore™ 2021 available at www.scopus.com/sources
- Send us an email
- Send us an email